Skip to main content

Table 1 BRCA1 Deficient-Like ( BD-L ) distribution in a breast cancer cell line panel

From: A BRCA1deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity

Cell line ER PR HER2 BRCA1 BD-Lmetagene value
HCC1143 - - - NA 207.2555
MDAMB415 + - - wt/- 208.6937
HCC1937 - - - m/- 226.181
BT20 - - - wt/- 227.6686
MDAMB468 - - - wt/- 260.2652
BT474 + + + wt/- 261.2111
HCC1428 + + - NA 265.375
MDAMB134VI + - - wt/wt 267.9736
SKBR3 - - + wt/- 277.6819
MCF10A - - - NA 285.3522
HCC1954 - - + NA 300.0448
HCC1500 - - - NA 300.3202
  1. Breast cancer cell lines selected for pharmacological inhibition evaluation. BD-L metagene values for the cell lines, as calculated from the Neve et al. [21] data set, are listed by increasing value. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein expression status are indicated. If known, the BRCA1 mutational status is noted (NA: not available).